Nkarta presents new preclinical data from engineered nk cell platform at sitc 36th annual meeting

South san francisco, calif., nov. 12, 2021 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the society for immunotherapy of cancer (sitc) 36th annual meeting and pre-conference programs.
NKTX Ratings Summary
NKTX Quant Ranking